{"article_title": "Sandoz Beats Amgen Bid To Delay Biosimilar Competition", "article_keywords": ["sandoz", "bid", "amgen", "competition", "delay", "beats", "version", "victory", "way", "zarxio", "judge", "york", "biosimilar", "approved", "view"], "article_url": "http://www.law360.com/articles/633756/sandoz-beats-amgen-bid-to-delay-biosimilar-competition", "article_text": "Sandoz Beats Amgen Bid To Delay Biosimilar Competition\n\nLaw360, New York (March 19, 2015, 7:13 PM ET) -- A California federal judge on Thursday handed Sandoz Inc. a major victory over Amgen Inc. in a high-stakes fight over the Affordable Care Act\u2019s approval pathway for biosimilars, clearing the way for sales of the first copycat biologic approved under the law.\n\n\n\nThe ruling from U.S. District Judge Richard Seeborg applies to Sandoz\u2019s Zarxio, a newly approved version of Amgen\u2019s blockbuster anti-infection drug Neupogen, and concerns the information-sharing and advance-notice provisions of the ACA\u2019s Biologics Price Competition and Innovation Act.\n\n\n\nOne part of the dispute centered...\n\nTo view the full article, register now.", "article_metadata": {"description": "A California federal judge on Thursday handed Sandoz Inc. a major victory over Amgen Inc. in a high-stakes fight over the Affordable Care Act&rsquo;s approval pathway for biosimilars, clearing the way for sales of the first copycat biologic approved under the law.", "apple-itunes-app": "app-id=934560389, app-argument=law360://www.law360.com/articles/633756/sandoz-beats-amgen-bid-to-delay-biosimilar-competition", "csrf-token": "PNAnYCwZJhHgSRq7wdkeZMP5CnvJtBbHbxkvfJ+VTUum9aciaZF5NEIeaMW8BfFGxchoDfud8PIan/h5OqUZ4w==", "csrf-param": "authenticity_token", "og": {"url": "http://www.law360.com/articles/633756/sandoz-beats-amgen-bid-to-delay-biosimilar-competition", "image": "https://www.law360.com/images/360.png", "type": "website", "title": "Sandoz Beats Amgen Bid To Delay Biosimilar Competition - Law360"}, "viewport": "width=device-width, initial-scale=1.0"}, "article_summary": "Sandoz Beats Amgen Bid To Delay Biosimilar CompetitionLaw360, New York (March 19, 2015, 7:13 PM ET) -- A California federal judge on Thursday handed Sandoz Inc. a major victory over Amgen Inc. in a high-stakes fight over the Affordable Care Act\u2019s approval pathway for biosimilars, clearing the way for sales of the first copycat biologic approved under the law.\nThe ruling from U.S. District Judge Richard Seeborg applies to Sandoz\u2019s Zarxio, a newly approved version of Amgen\u2019s blockbuster anti-infection drug Neupogen, and concerns the information-sharing and advance-notice provisions of the ACA\u2019s Biologics Price Competition and Innovation Act.\nOne part of the dispute centered...To view the full article, register now."}